Keeping Elders in the Village: Tanana Chiefs Conference Community Health Outreach Program
Tanana Chiefs Conference delivers home- and community-based services in remote villages across the interior of Alaska to help elders stay in their communitie...
By: CMSHHSgov
Original post:
Keeping Elders in the Village: Tanana Chiefs Conference Community Health Outreach Program - Video
Anthony Brown #39;s Health Care Special Interests
While Lt. Governor Brown was busy raking in money to the tune of more than $40000 between 2011 and 2014 from special interests directly tied to the exchange...
By: Doug Gansler
Go here to see the original:
Health Care Divide
Rainbow Push holds health care summit in Cleveland to discuss the "medical divide"
By: WEWS NewsChannel5
See the article here:
HCCA's 18th Annual Compliance Institute features 146 sessions, 231 speakers, nine educational tracks over four days
MINNEAPOLIS, Minn., Jan. 23, 2014 /PRNewswire-USNewswire/ -- Today's health care industry is undergoing massive restructuring and compliance professionals must keep abreast of all the new laws, regulations, and enforcement actions to meet the challenge this reform brings. More than 2,000 health care compliance professionals will be in San Diego to address this rapidly changing environment at the Health Care Compliance Association's (HCCA) 18th Compliance Institutethe largest and most comprehensive compliance conference developed for and by compliance, HCCA announced today.
"The health care industry is central to our economy and undergoing unprecedented change. New regulations and established ones both pose substantial requirements that health care providers can't afford not to meet," said HCCA Chief Executive Officer Roy Snell. "Fortunately there are some real success stories out there, and this conference gives attendees a chance to learn from them and bring them back to their organizations."
The Compliance Institute is the primary education and networking event for professionals working in the health care compliance profession. At this meeting, attendees learn the latest methods and strategies for developing and improving their compliance programs in this fast changing health care industry. It offers nine learning tracks including General Compliance and Hot Topics, Long-Term Care, Privacy & Security, Physician Compliance, Compliance Lawyer, Auditing & Monitoring, Quality of Care, How to Succeed as a Compliance Professional, and Advanced Discussion Groups.
Session topics include:
-Handling Multiple External Audits and Compliance Reviews,
-Evolving Cyber Threats to PHI,
-Medicaid Enforcement Update,
-It's Not Child's Play: Children's Hospitals Compliance Issues,
-Top 10 Conflicts of Interest Developments Compliance Professionals Need to Know About,
See more here:
Contact Information
Available for logged-in reporters only
Newswise A new study conservatively estimates that one in five women with ovarian cancer has inherited genetic mutations that increase the risk of the disease, according to research at Washington University School of Medicine in St. Louis.
Most women in the study would have been unaware of a genetic predisposition to ovarian cancer because they didnt have strong family histories that suggested it.
The research, published Jan. 22 in Nature Communications, is the first large-scale analysis of the combined contributions of inherited and acquired mutations in a major cancer type. The inherited mutations by themselves are unlikely to cause ovarian cancer but may conspire with other genetic changes acquired over a womans lifetime to tip the balance toward cancer, the researchers said.
Earlier studies that have looked at inherited susceptibility to ovarian cancer have focused on women with known family histories of the disease. For the current study, however, the researchers studied 429 women with ovarian cancer that appeared to develop sporadically, meaning the women did not have known family histories of the disease.
Using advanced genomic analysis, we found that 20 percent of women with ovarian cancer had inherited mutations in a gene pathway known to be important in inherited breast and ovarian cancer. That number seems pretty high, explained senior author Li Ding, PhD, assistant director at The Genome Institute at the School of Medicine and a research member of Siteman Cancer Center. This tells us that we need to find better ways to screen women for ovarian cancer, even if they dont have family histories of the disease.
Ovarian cancer strikes an estimated 22,000 women annually. Its symptoms are nonspecific and include bloating, pelvic pain and frequently feeling the need to urinate. Most women arent diagnosed until the cancer has spread, leading to a poor five-year survival rate of 43 percent.
Women with ovarian cancer in the study did not have known family histories of breast or ovarian cancer or rare cancer syndromes, all of which can increase the odds of developing ovarian tumors. The women ranged in age from 26 to 89, and 90 percent were Caucasian.
The researchers, including Washington University first authors Krishna Kanchi, Kimberly Johnson, PhD, and Charles Lu, PhD, performed a genetic analysis of each womans tumor and her own DNA, taken from a skin sample. By comparing the genetic sequences side-by-side, they identified the acquired mutations in individual tumor samples. In addition, by comparing the patients DNA samples with the DNA of 557 women who did not have ovarian cancer and served as controls, the researchers found inherited mutations.
See more here:
Study Shows 1 in 5 Women with Ovarian Cancer Has Inherited Predisposition
PUBLIC RELEASE DATE:
22-Jan-2014
Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2156 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, January 22, 2014Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cancer Biotherapy and Radiopharmaceuticals website.
"High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines" describes a statistically significant improvement in survival for patients who received IL2 plus tumor cell-based immunotherapy. Authors Robert Dillman, Carol DePriest and Stephanie McClure, Hoag Institute for Research and Education, Hoag Family Cancer Institute, and Cancer Biotherapy Research Group, Newport Beach, CA, found that administration of immunotherapy after IL2 treatment resulted in longer patient survival than if individuals were vaccinated before receiving IL2.
"This is an important addition to the literature on IL2 treatment for metastatic melanoma demonstrating that personalized vaccine therapy contributed to an increased survival rate," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham.
###
About the Journal
Cancer Biotherapy and Radiopharmaceuticals, published 10 times a year in print and online, is under the editorial leadership of Editors Donald J. Buchsbaum, PhD and Robert K. Oldham, MD, Lower Keys Cancer Center, Key West, FL. Cancer Biotherapy and Radiopharmaceuticals is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways. Tables of content and a sample issue are available on the Cancer Biotherapy and Radiopharmaceuticals website.
About the Publisher
Read the original post:
Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
PUBLIC RELEASE DATE:
21-Jan-2014
Contact: Sophie Mohin smohin@liebertpub.com 914-740-2100 x2254 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, January 21, 2014 Too much information can be overwhelming, but when it comes to certain types of data that are used to build predictive models to guide decision making there is no such thing as too much data, according to an article in Big Data, the highly innovative, peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Big Data website.
To determine whether more data is really better for predictive modeling, Enric Junqu de Fortuny and David Martens, University of Antwerp, Belgium, and Foster Provost, New York University, NY, tested nine different applications in which they built models using a particular type of data called fine-grained data, such as observing an individual's behavior in a certain setting. In the article "Predictive Modeling with Big Data: Is Bigger Really Better?" the authors state that "certain telling behaviors may not be observed in sufficient numbers without massive data."
"The power of any analytic tool is in using it appropriately," says Founding Editor, Edd Dumbill. "Sweeping assumptions such as 'bigger is better' can be dangerous. This paper significantly advances our knowledge of when massive datasets improve decision-making ability."
###
About the Journal
Big Data, published quarterly in print and online, facilitates and supports the efforts of researchers, analysts, statisticians, business leaders, and policymakers to improve operations, profitability, and communications within their organizations. Spanning a broad array of disciplines focusing on novel big data technologies, policies, and innovations, the Journal brings together the community to address the challenges and discover new breakthroughs and trends living within this information.
About the Publisher
More:
AP/January 22, 2014
CONCORD, N.H. (AP) New Hampshires House killed a bill Wednesday that would have required genetically modified foods to be labeled.
The House voted 185-162 to kill the bill, despite supporters arguments it is time for states like New Hampshire to lead on the issue regardless of the federal governments position.
Supporters argued New Hampshire residents have a right to know whether their food is produced with genetic engineering, but critics said the federal Food and Drug Administration has not mandated the labeling because it determined the foods are safe.
The reality is most of us are living every day with the benefits of genetic engineering, said Rep. Linda Lauer, D-Bath. She said insulin has been genetically engineered since 1982. Prior to that insulin was taken from the pancreas of farm animals, she said.
Lauer said the labeling required under the bill would not tell consumers what was in the food, only that it had been genetically engineered. She said the label wouldnt provide accurate information about the foods. For example, genetically engineered beets are used to produce sugar, which is a pure chemical compound. Despite its purity, any foods containing the sugar would have to be labeled, she said.
But Rep. Peter Bixby, D-Dover, said people have a right to know if genetic engineering modified the foods.
People are responsible for their own decisions, but to make those decisions they need information, he said.
But opponents said wary consumers could buy organic foods or foods labeled as not being genetically modified. They said the industry is beginning to respond to consumers wishes for genetically engineered foods to be labeled,
The market will solve this problem. It moves a little slow, but it will solve the problem, said Rep. Robert Haefner, R-Hudson.
Read this article:
New gene therapy success holds promise for degenerative retinal diseases
Gene therapy researchers at UMass Medical School focused on degenerative retinal diseases are calling a promising new study out of University of Oxford the "...
By: UMass Medical School
Continue reading here:
New gene therapy success holds promise for degenerative retinal diseases - Video
As part of my 2014 predictions, I argued gene therapy would get hot and investor interest would turn toward the monogenic programs at Sangamo Biosciences (SGMO). The partnership announced on Jan. 9 between Biogen Idec (BIIB) and Sangamo confirmed my prediction to a certain extent, albeit sooner in the year than I expected.
Let's discuss what the Biogen partnership means for Sangamo moving forward, and discuss the implications for other gene therapy stocks like Bluebird (BLUE) and Acceleron (XLRN)?
The partnership covers two Sangamo programs: sickle cell disease (SCD) and beta-thalassemia (BT). Sangamo will receive a $20 million upfront payment and is eligible for just about $300 million in future milestones. While it is not explicitly stated, $15 million of those milestones appear to be related to the start of a phase I trial. Sangamo will receive double-digit royalties on sales and retains the right to co-promote in the U.S., assuming drug approval, of course.
Summed up, the new partnership is a nice entry into the gene therapy business for Biogen and continued validation of the Sangamo monogenic disease pipeline.
Sobek has no position in any stocks mentioned in this column.
View post:
The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron
SCIENTISTS in Florida, USA, are studying gene therapy to cure genetic eye diseases.
Prof. Galileo Encabo, senior biological scientist at the Department of Opthalmology of the University of Florida, said they have conducted successful human clinical trials, but it would take years before the technology can be made available to the public.
From clinical trials, it takes a few years to make it available for public use. We will have to find a pharmaceutical firm willing to produce (the technology), then we have to get approval from the different bureaucrats, Encabo told reporters.
Gene therapy is the introduction of new genes into human cells to treat a disease. It involves replacing, correcting or removing an abnormal gene.
Encabo held a seminar at the University of the Philippines Cebu yesterday. He was a graduate and a former professor of the university.
The two-hour seminar, held at the UP Cebu Union building, was organized by the UP Cebu Central Visayas Studies Center in partnership with the universitys Sciences Cluster.
It aims to inspire students to pursue studies on molecular genetics.
The University of Florida is collaborating with 65 other institutions in its research on gene therapy.
Encabo said the persons who were subjected to the clinical trials improved their vision, with some increasing their visual ability 10,000 times.
The success of the human clinical trials, he said, will attract more private organizations to support the experiments and validate the whole concept of human gene therapy.
Visit link:
PUBLIC RELEASE DATE:
22-Jan-2014
Contact: Kim Blakely krb13@uw.edu 206-685-1323 University of Washington
Preclinical studies show that gene therapy can improve muscle strength in small- and large-animal models of a fatal congenital pediatric disease known as X-linked myotubular myopathy. The results, appearing in the Jan. 22 issue of Science Translational Medicine, also demonstrate the feasibility of future clinical trials of gene therapy for this devastating disease.
Researchers, based at the University of Washington, Seattle, Washington, Gnthon, France, Boston Children's Hospital in Massachusetts, and Virginia Polytechnic Institute and State University (Virginia Tech) in Blacksburg, Virginia, conducted the study. The scientists found that both mice and dogs responded from a single intravascular injection of AAV, produced at Gnthon, with robust improvement in muscle strength, corrected muscle structure at the microscopic level, and prolonged life. No toxic or immune response was observed in the dogs.
These results demonstrate the efficacy of gene replacement therapy for myotubular myopathy in animal models and pave the way to a clinical trial in patients.
Children born with X-linked myotubular myopathy, which affects about 1 in 50,000 male births, have very weak skeletal muscles, causing them to appear floppy, with severe respiratory difficulties. Survival beyond birth requires intensive support, often including tube feeding and mechanical ventilation, but effective therapy is not available for patients, and most die in childhood.
Alan H. Beggs of Boston Children's Hospital, co-senior author on the paper, has studied the mutated gene, known as MTM1, for many years and previously showed that replacing missing myotubularin protein effectively improved MTM muscles' ability to contract.
Based on seminal work on local and systemic administration in a mouse model of the disease performed by Anna Buj-Bello at Gnthon since 2009, Martin K. Childers, a professor of rehabilitation medicine and a regenerative medicine researcher at the University of Washington, worked with the Buj-Bello and Beggs groups.
They tested gene therapy using an engineered adenovirus vector, created by Gnthon. The vector is a vehicle for delivering a replacement MTM1 gene into cells. The researchers used two animal models: mice with an engineered MTM1 mutation and dogs carrying a naturally occurring MTM1 gene mutation. These mutant animals appear very weak with shortened lifespans, similar to patients with myotubular myopathy.
See the article here:
Gene therapy leads to robust improvements in animal model of fatal muscle disease
Thinking Strategically About Intelligent Decision Management: Technology Futurist/Speaker Jack Shaw
Hi. I #39;m Jack Shaw, the Business Technology Futurist. This is one in a series of brief videos in which I will discuss intelligent systems and how you, and you...
By: Jack Shaw
View post:
Original Toyota MR2 was a Showcase of Futurism
Old Japanese cars have a bad tendency to rust. It #39;s just a fact and the first-generation Toyota MR2 (codenamed AW11) that launched in 1984 is no exception. Y...
By: EasyDosh
Continued here:
S
The Paleofuture blog turns 7 years old today! And you can now find every Paleofuture post ever writtenright here at Gizmodo.
When I came on board at Gizmodo this past May, I brought my entire Paleofuture archive with me. Every post I've ever written under the Paleofuture nameat Paleofuture.com and Smithsoniancan now be found here at Paleofuture dot Gizmodo dot com. All you need to do is use that little search bar in the upper lefthand corner.
For instance, if you're interested in Nikola Tesla's predictions for the future, just type in "Tesla." Interested in robots or monorails or Disney? Same deal.
Paleofuture explores how people of the past imagined the future, and we're always making more futurism. So conceivably I could do this forever. But we'll see about that.
We're seven years in and (amazingly) I'm not sick of the topic yet. I really do think that futurism provides the most fascinating lens through which to study historyfrom the shiny plastic utopias of the 1950s to the dark polluted dystopias of the 1970s.
And as I've said before, looking at the accuracy of past predictions is really just a jumping off point. Determining if an old prediction was "right" is fun, but the truly interesting question is why people made their particular prediction to begin with. What was the context of the prediction? What were people excited or terrified about? As always, predictions say more about the person making them than they do about the actual future.
So here's to seven more years of our weird and wonderful visions of yestermorrow, and definitely drop me a line (novak@gizmodo.com) if you find something paleofuture-y that I haven't covered.
Thanks for reading.
Image: Scanned from the April 27, 1958 edition of Arthur Radebaugh's Sunday comic strip "Closer Than We Think"
Follow this link:
PianoKad play "The Price of Freedom" from FFVII Crisis Core
https://www.facebook.com/PianoKad.Officiel Oyo ! Le thme principal du magnifique jeu "Final Fantasy VII Crisis Core" qui retrace les origines de l #39;opus sort...
By: PianoKad
Original post:
PianoKad play "The Price of Freedom" from FFVII Crisis Core - Video
Dragon Gate USA Freedom Fight DVD Trailer With Match Of The Year!
DGUSA Freedom Fight 2012 is now shipping on DVD from the http://www.DGUSA.tv Store. It features the match that the fans voted as the DGUSA/EVOLVE match of th...
By: DGUSA evolve
Follow this link:
Dragon Gate USA Freedom Fight DVD Trailer With Match Of The Year! - Video
Assassin #39;s Creed IV Freedom Cry Detonado Parte 8: Investigao Cientfica [1080p PT-BR]
Assassin #39;s Creed IV Black Flag Freedom Cry DLC - Parte 8 Investigao Cientfica 100% Sincronizao (Grito de Liberdade DLC) Gameplay 1080p HD PC PS4 Xbox On...
By: blackaiogamer
Go here to read the rest:
Assassin's Creed IV Freedom Cry Detonado Parte 8: Investigação CientÃfica [1080p PT-BR] - Video
Assassin #39;s Creed IV Freedom Cry Detonado Parte 9: Explorando o Mar [1080p PT-BR]
Assassin #39;s Creed IV Black Flag Freedom Cry DLC - Parte 9 Explorando o Mar 100% Sincronizao (Grito de Liberdade DLC) Gameplay 1080p HD PC PS4 Xbox One No e...
By: blackaiogamer
View original post here:
Assassin's Creed IV Freedom Cry Detonado Parte 9: Explorando o Mar [1080p PT-BR] - Video
The Stanley Parable Pt3: The Freedom Ending! (Should We Do More?)
Please comment and like the video for more! If you want up to date news on A ducks opinion with pictures and screenshots plus videos. Like us on Facebook! it...
By: ADucksOpinion
See the article here:
The Stanley Parable Pt3: The Freedom Ending! (Should We Do More?) - Video